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Abstract
Sarcoidosis is a systemic inflammatory disease of unknown aetiology. In India, sarcoidosis is an under-diagnosed disease. All ethnic
groups in the Indian sub-continent are affected by sarcoidosis. Most of the Indian patients with sarcoidosis are males, and a majority
of them present in their fourth or fifth decade of life. Many patients with sarcoidosis are asymptomatic with incidental findings on
the chest radiograph. Depending on the organ systems involved, patients with sarcoidosis present themselves to various specialities,
with pulmonary involvement being the commonest. The diagnosis is based on a compatible clinical and/or radiological picture,
histopathological evidence of non-caseating granulomas in tissue biopsy specimens, and exclusion of other diseases that can
produce similar clinical or histopathological appearances. The disease runs a benign course with spontaneous remission of the
activity. Only a minority of the patients develop complicated disease though some degree of residual pulmonary function
abnormality persists. A high index of clinical suspicion and focussed attempts to secure histopathological confirmation of the
diagnosis early in the illness are required to ascertain the diagnosis. For asymptomatic patients with pulmonary sarcoidosis, no
therapy is required. In symptomatic patients, or those with complications, corticosteroids remain the mainstay of treatment and
sometimes steroid-sparing alternative treatments may be beneficial. Treatment should be tailored to suit the needs of the individual
patient under close clinical monitoring.
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Introduction
Sarcoidosis is an intriguing multisystem disorder of
unknown aetiology that occurs worldwide and affects
people of all ages and races1,2. Patients with this
intriguing disease may often be asymptomatic with
incidental findings of mediastinal lymphadenopathy
on the chest radiographs. Depending on the organ
systems involved, patients with sarcoidosis present
themselves to various specialities with the lungs being
the most commonly affected sites2-4. Sarcoidosis has
been traditionally thought to be uncommon in tropical
countries like ours and remained unreported from
India till the late 1950s. Most sarcoidologists in India
feel that remarkable resemblance to tuberculosis and
lack of facilities to per form invasive diagnostic
procedures and lack of awareness among physicians
and pathologists regarding the disease have all been
the reasons for under-reporting of the disease.
However, several case reports and a few large series3-8
have indeed been reported from India, indicating that
the disease is not so rare as is presumed. In this review,
we have attempted to provide a critical overview
regarding various aspects of sarcoidosis as has been
reported in the Indian context.
Burden of sarcoidosis
 Prevalence of sarcoidosis is higher in the Scandinavian
countries. In other areas of the world, epidemiological
observations have been variable. The true burden of
sarcoidosis in India is not clearly known as reliable
epidemiological data are not available. It has been
estimated that sarcoidosis constituted 10 to 12 cases/
1,000 new registrations annually at a Respiratory Unit at
Kolkata and 61.2/100,000 new cases seen at the
Vallabhbhai Patel Chest Institute (VPCI), Delhi9. We feel that
these observations are likely to be underestimates and
the actual burden of sarcoidosis is likely to be more than
what is reflected in these figures because many cases
remain undiagnosed or unreported.
Over the last two decades, the patients with sarcoidosis
seen by us at the All India Institute of Medical Sciences
(AIIMS), New Delhi, one of the largest tertiary care referral
centre were from almost every state in the country3,4,10.
This observation and review of published literature from
India suggests that sarcoidosis occurs in all ethnic groups
and communities in India5-8,11.
Aetiology
Inspite of the scientific and technological advances, the
aetiological cause of sarcoidosis has not been unravelled.
The cause of sarcoidosis is still obscure, continues to elude
us and remains an enigma. It is also not clear whether
sarcoidosis is caused by a single agent, several related
agents, or multiple factors. Genetic factors have been
thought to play a role in the pathogenesis of sarcoidosis
for a long time. It is unlikely that any single gene is involved
in the pathogenesis of sarcoidosis. Probably, genetically
predisposed hosts are exposed to antigens that trigger
an exaggerated immune response and this results in the
formation of granulomas. Although no significant
association has been reported between sarcoidosis and
occurrence of HLA phenotypes, the most consistent allele
found associated with sarcoidosis has been HLA-B8 in
some of the western studies12,13. Recent immunogenetic
study results based on the molecular typing of HLA alleles
of sarcoidosis patients by the authors’ group14 revealed
positive association of DRB1*11, DRB1*14, DQA1*0101/4,
and DQB1*0503 class II alleles with the disease. Follow-
up data suggested predominant occurrence of DRB1*14
and its linked DQ alleles in patients with insidious onset,
advanced disease on chest radiographs, and chronic
course with frequent relapses on tapering-off the
prednisolone treatment. Furthermore, multivariate logistic
regression analysis revealed that the presence of
DRB1*11[odds ratio (OR) 9] and DRB1*14 (OR 7), and
absence of DRB1*07 (OR 63 and DQB1*0201(OR 3) alleles,
were independent predictors of sarcoidosis14.
Observations on community out-breaks, work-related risk
of sarcoidosis for nurses, and a study tracing the case
contacts on the Isle of Man15-17 suggest a person-to-person
transmission, or shared exposure to an environmental
agent. Transplantation of sarcoidosis by cardiac and bone
marrow transplantation18,19 suggests an infectious
aetiology. These issues need further clarification in the
studies addressing the microbial aetiology of sarcoidosis.
Since many non-infectious agents present in the
environment can induce granulomatous reaction, there
appears to be some role for exposure to an environmental
agent in the causation of granulomatous inflammation in
patients with sarcoidosis20. Most of the current evidence
suggests some role for beryllium20. While other agents
such as clay soil, pine dust, and talc have been postulated,
there is no significant published evidence to support this
view. However, the pathogenetic mechanisms involved
require further elucidation.
Clinical presentation
Clinical presentation of sarcoidosis as seen in Indian
patients is contrasted with the clinical observations
from the West in Table I. Sarcoidosis is predominantly
a disease of adults, and seldom seems to affect
children. While more than 70 per cent of the patients
in the West were less than 40 years of age, sarcoidosis
in India has a late onset by nearly a decade (Table I).
While the disease has a slight female preponderance
globally, sarcoidosis is commoner in males in India
( Table I). This appears to be true even after giving
allowance to the fact that males seek medical care
more often than females in our hospitals.
Acute presentation in the form of “Löfgren’s syndrome”
and “Heerfordt’s syndrome” (fever, parotid enlargement,
facial palsy, and anterior uveitis) is uncommon in patients
from the Indian sub-continent. Familial sarcoidosis has
been described with a rate of at least 19% in affected black
families and 5% in white families28. Familial sarcoidosis has
occasionally been reported from India also3,5,29,30. In the
series reported by us3, familial involvement was observed
in 6 of the 106 biopsy-proved patients with sarcoidosis.
Subsequently, we have observed familial sarcoidosis in
four more families. Thus, 10 of the 210 patients (5%) seen
by us between January 1980 and August 2003 had familial
involvement and brother-brother involvement was most
frequently encountered.
The constitutional symptoms such as fever, fatigue,
malaise, and weight loss have been observed to occur
more often in Indian patients than in patients from the
West (Table I). Fever-malaise dissociation has been
reported to be common in Indian patients with
sarcoidosis3-5,10,11,29.
Pulmonary involvement is, by far the commonest, and has
been reported in about 90 per cent of the patients3-5,10,11.
Patients may complain of cough which may be non-
productive, dyspnoea, and chest pain. Haemoptysis and
clubbing are rare and chest signs on auscultation may be
present in fewer than 20 per cent of patients. Airway
hyperactivity has been reported in up to 20 per cent of
patients with sarcoidosis3,4. Sometimes, reversible airways
obstruction and clinical presentation mimicking bronchial
asthma with seasonal exacerbations may also be
encountered3,4.
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Table I : Clinical profile, laboratory characteristics, radiological findings, and treatment in Indian patients with
sarcoidosis with those from the West.
Sharma SK et al Other Indian studies Western studies
(n = 210)* (n = 409)† (n = 8137)‡
Females 39 43-71 57-61
Under 40 years 34 25-66 70-86
Thoracic involvement 98 61-97 88-99
Ocular involvement 17 08-40 4-27
Erythema nodosum 07 02-20 11-34
Other Skin lesions 35 10-24 –
Parotid enlargement 11 03-15 0.5-6
Neurological involvement 10 01-11 0.3-9
Fever 56 35-54 –
Constitutional symptoms§ 42 14-57 –
Arthralgias/arthritis|| 39 18-35 40
Cardiac involvement 07 0-12 03
Peripheral lymphadenopathy 43 19-42 8-27
Hepatomegaly 42 14-42 12
Splenomegaly 17 02-27 0.3-10
Radiologic stage at presentation
0 01 01-03 4-13
I 34 45-62 58-65
II 57 30-34 22-31
III 08 07-18 7-13
Kveim positive Not done 45-96 73-84
Mantoux negative 88** 59-97 55-70
Hypercalcaemia 13†† 18-40 0.7-18
Hypercalciuria 32†† 10-49 2-50
All values expressed as percentages are corrected to the nearest round figure.
* Data appended from “Sharma SK, Mohan A. Sarcoidosis: global scenario and Indian perspective. Indian J Med Res 2002; 116: 221-47” (reference
4); † Cumulative figures from five series reference 5 (n = 125), reference 6 (n = 40), reference 7 (n = 155), reference 8 (n = 60), and reference 21
(n = 29); ‡ Cumulative figures from six series reference 23 (n = 818), reference 24 (n = 797), reference 25 (n = 2006), reference 26 (n = 3676),
reference 27 (n = 125), reference 28 ( n =715); § Constitutional symptoms included weight loss, fatigue, malaise; || Clear distinction between
arthralgias and arthritis is not clearly mentioned; ** Tested in 184 patients; †† Tested in 148 patients.
Cutaneous involvement occurs in about 11 to 34 per
cent of patients with sarcoidosis (Table I). These include
er ythema nodosum, lupus pernio, plaques,
maculopapular lesions subcutaneous nodules,
changes in old scars, alopecia, and hypo- and hyper-
pigmented areas. Sarcoidosis skin lesions seldom
produce itching or pain, and they do not ulcerate.
Ocular involvement may occur in 4 to 27 per cent of
patients with sarcoidosis ( Table I). All the parts of the
eye or orbit can be affected. Uveitis is the most
common manifestation and the clinical presentation
may be acute or chronic31. Other ocular manifestations
include conjunctival foll icles, lacrimal gland
enlargement, dry eye (keratoconjunctivitis sicca),
dacryocystitis, and retinal vasculitis31. Peripheral
lymphadenopathy has been observed in 8 to 44 per
cent of patients ( Table I). Rarely, intra-abdominal
lymphadenopathy may also be present3,4. Joint
symptoms have been described in 30 to 50 per cent of
patients with sarcoidosis (Table I). These may be acute
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and transient, or chronic and persistent. Acute onset
ar thritis – often reported from the west – is
uncommon, and arthralgias are far more common than
arthritis in Indian patients ( Table I). Unilateral or
bilateral painless parotid gland enlargement occurs in
1 to 10 per cent of patients (Table I) and may result in
“chipmunk cheeks” appearance.
Hypercalcaemia and hypercalciuria are often encountered
in patients with sarcoidosis. Persistent hypercalcaemia and
hypercalciuria can result in nephrocalcinosis,
nephrolithiasis, and renal failure. Hypothalamic or pituitary
involvement can result in diabetes insipidus. Uncommonly,
hypothyroidism, hyperthyroidism, hypothermia, adrenal
suppression, and anterior pituitary involvement can
occur3,4. Clinical evidence of myocardial involvement has
been reported in about five per cent of patients with
sarcoidosis and ranges from benign arrhythmias or high-
degree heart block to sudden death32. Endomyocardial
biopsy is useful in demonstrating granulomas and
confirming the diagnosis of cardiac sarcoidosis. Cardiac
involvement has seldom been systematically studied in
Indian patients with sarcoidosis, and abnormalities
observed on the electrocardiogram (ECG) have been the
most commonly described abnormalities3-5,10,11. The
gastrointestinal tract is involved in less than one per cent
patients with sarcoidosis2-4. Although granulomas may be
found in 50 to 80 per cent of liver biopsy specimens,
palpable hepatomegaly has been observed in 8 to 43 per
cent patients (Table I). Hepatic involvement rarely causes
portal hypertension, hepatic failure, or increased mortality
related to liver dysfunction3,4,33,34. Clinical evidence of the
involvement of the nervous system occur in 0.3 to 13 per
cent of patients with sarcoidosis (Table I). Cranial nerve
involvement, particularly facial palsy and hypothalamic
and pituitary lesions, are common; space-occupying mass
lesions, and peripheral neuropathy, have also been
reported ( Table I). Similar observations have been
reported in the studies from India3-5,10.
Sarcoidosis can virtually involve every body system and
unusual presentation of the disease can be a diagnostic
problem. There have been very few reports regarding
uncommon manifestations in patients with sarcoidosis
from India and these are depicted in Table II3,4,33,35-40.
Awareness regarding uncommon manifestations of
sarcoidosis will facilitate early confirmation of diagnosis.
Radiological manifestations
The chest radiographs reveal abnormalities in more than
90 per cent of the patients with sarcoidosis at presentation.
The characteristic radiological finding in patients with
pulmonary sarcoidosis is bilateral hilar lymphadenopathy.
Pulmonary sarcoidosis is staged by the traditional
radiographic criteria as follows: stage 0 – normal chest
radiograph; stage I – bilateral hilar lymphadenopathy
without parenchymal infiltrates; stage II – bilateral hilar
lymphadenopathy with parenchymal infiltrates; and
stage III – parenchymal infiltrates without hilar
lymphadenopathy. In the western literature, most of the
patients had stage I disease, while most of the Indian
patients with sarcoidosis presented with stage II disease
(Table I). In Indian patients with sarcoidosis, it has been
observed that while the chest radiographs may look
startling, patients may manifest minimal symptoms and
this has been termed clinico-radiographic dissociation)3-5,11.
Parenchymal infiltrates that are often bilateral and
symmetrical involving the upper lobes more often are
evident in 25 to 50 per cent of the patients with pulmonary
sarcoidosis3,4. Other patterns observed include reticular,
reticulonodular, or focal alveolar opacities, miliary
mottling, or ground glass appearance. Pleural involvement
is rare and includes small pleural effusion which may be
bilateral at times, thickening, pleural plaques or nodules.
Occurrence of bilateral recurrent pneumothoraces has
also been reported41. While computerised tomographic
scan (CT scan) of the chest is not routinely required for
diagnostic evaluation or follow-up of patients with
sarcoidosis, it is useful in detecting enlarged lymph nodes
or parenchymal infiltrates that are not evident on the
conventional chest radiograph and is therefore more
useful in patients with atypical or uncommon
manifestations. Characteristic features of sarcoidosis on
CT scan include central bronchovascular thickening and
nodularity, miliary nodules, thickening of interlobular
septae, luminal irregularity, ground-glass attenuation,
architectural distortion, conglomerate masses,
honeycombing and cystic destruction, alveolar
consolidation, parenchymal and pleural nodules. The
lesions are most commonly located along the
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peribronchovascular sheath lymphatics and sometimes
in subpleural and interlobular septal lymphatics42. CT scan
of the abdomen is also useful in identifying uncommon
lesions such as lesions in liver and spleen, retroperitoneal
and abdominal lymphadenopathy3,4. CT scan and
gadolinium (gadopentetate demeglumine)- enhanced
magnetic resonance imaging (MRI) have been found to
be useful in localising neurosarcoidosis and sarcoidosis of
the bones3,4,10.
Table II : Uncommon manifestations observed in
patients with sarcoidosis from India.
Thoracic
– superior venacaval obstruction
– transient paralysis of phrenic and recurrent
laryngeal nerves
– bullous lesions in the lungs
– chronic respiratory failure
– narrowing of main bronchi, fixed upper airways
obstruction
– clinical presentation mimicking bronchial asthma
with seasonal exacerbations
– pleural effusion, nodules, and pneumothorax
Gastrointestinal
– cirrhosis of liver with portal hypertension
Abdominal
– intra-abdominal lymphadenopathy
– hypodense lesions in liver and spleen
Renal
– sarcoid nephritis
– gross digital clubbing
Cardiac involvement
– complete heart block
– congestive heart failure
– supraventricular, ventricular ectopics, and recurrent
ventricular tachycardia
Neurological
– bilateral sequential facial nerve palsy
– optic neuritis
– proximal myopathy
– multiple brainstem lesions
– pituitary stalk lesion
– optic atrophy
Others
– breast lumps
– glaucoma
Data is from references 3,4,33,35-40.
Laboratory investigations
Cutaneous anergy is considered to be a cardinal feature
of sarcoidosis. Tuberculin skin test is often negative in
nearly two-thirds of the patients with sarcoidosis (Table
I). Haematological abnormalities include anaemia,
leucopaenia, lymphopaenia, eosinophilia, and
monocytosis among others3,4,10. Polycythaemia has
occasionally been reported. Since several steroid-sparing
alternative treatment modalities such as cytotoxic agents
can affect these parameters, physicians treating
sarcoidosis should be aware of these abnormalities.
Hypercalcaemia has been reported to occur in 2 to 63 per
cent of patients with sarcoidosis and hypercalciuria is
three times more common than hypercalcaemia3-5,10.
Elevated serum aminotransferase, alanine
aminotransferase, and alkaline phosphatase have also
been described3,4,10. In a large Indian study3,
hyperuricaemia was observed in 41 per cent of the
patients tested. All the patients with hyperuricaemia had
stage II disease3. Ureteric stones occurred in five of the
210 patients seen by the authors4. These observations
merit further study.
Pulmonary functions
The lung function abnormalities of sarcoidosis include
decreased lung volumes and diffusing capacity3,4,10.
However, these abnormalities are not specific for
sarcoidosis and are typical for interstitial lung disease
of any aetiology. Pulmonary function abnormalities are
present in about 20 per cent of the patients with stage
I sarcoidosis, but occur in 40 to 70 per cent patients
with stages II or III3,10,11. Airways involvement has been
obser ved in about a third of the patients with
sarcoidosis3,4. Very little has been systematically
documented regarding the pulmonary function
abnormalities in patients with sarcoidosis and the
effect of prednisolone treatment on them from India.
In the only study of its kind reported from India3,
pulmonary function abnormalities were suggestive of
a mixed obstructive and restrictive ventilatory defect;
however, an obstructive defect was predominantly
observed. Review of published evidence suggests that
the physiological abnormalities poorly correlate with
the pathological findings1.
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Bronchoscopy
Flexible fibreoptic bronchoscopy (FOB) and
bronchoscopic techniques such as trans-bronchial
lung biopsy ( TBLB), endobronchial biopsy,
transbronchial needle aspiration ( TBNA), and
bronchoalveolar lavage (BAL)43-46 have been found to
be useful for studying the disease and procuring tissue
for the confirmation of a diagnosis of sarcoidosis.
Bronchoscopic appearances of sarcoidosis include
nodules, plaques, erythema and cobble stone
appearance. TBLB has a high diagnostic yield because
the lesions of sarcoidosis are distributed along the
bronchovascular bundle7,47.
BAL has very little practical clinical or prognostic utility
and has been utilised as a research tool43-46. Classically, BAL
fluid reveals lymphocytic alveolitis with elevated CD4/CD8
ratios and increase in cell recovery43-46. A negative
correlation between bronchoalveolar lavage lymphocytes
and pulmonary diffusing capacity45 have also been
reported in patients with sarcoidosis. In patients with
sarcoidosis, glucocorticoid receptor (GR) content of the
BAL fluid cells is increased and a major contribution to
this is made by the lymphocytes44. Log transformation of
the ratio of lymphocyte per cent (L) and the per cent of
polymorphs + 1 (L/P+1) in the BAL fluid was found to be
useful in differentiating these two conditions46.
Elevated levels of serum ACE have been observed in 40
to 90 per cent of patients with sarcoidosis3-5,10 and is
considered to be a marker of disease activity in reports
from the West. Experience with this expensive test in the
Indian context has been controversial. Gupta et al5
observed elevated SACE levels in three-fourths of their
Indian patients. However, the authors’ group48 did not find
higher SACE activity in patients with active sarcoidosis
compared to those with inactive disease. Moreover, there
was no significant difference in the SACE activity among
different stages in patients with active sarcoidosis47. One
of the reasons for these differences could be differences
in the protocols followed for SACE level estimation, lack
of uniform laboratory standards, and non-availability of a
definitive “gold-standard” for the confirmation of the
diagnosis of sarcoidosis. 67Gallium scanning has been
found to be a useful adjunct in diagnosing sarcoidosis49.
However, a negative gallium scan does not rule out active
sarcoidosis. Clinicians should keep these facts in mind
before ordering these expensive investigations.
Diagnosis
As there is no definitive “gold standard” for the diagnosis,
sarcoidosis is essentially a diagnosis of exclusion.
Estimation of serum ACE activity67, gallium scanning have
poor specificity; the antigen required for Kviem-Siltzbach
test is not widely available in India, not well standardised,
and not approved for general use. Thus, all suspected cases
of sarcoidosis must be confirmed by tissue biopsy to
exclude mycobacterial, fungal, and other granulomatous
infections or malignant conditions. Specimens must be
procured for histopathological examination from the most
accessible site with the least invasive method. More
recently, tran-sbronchial lung biopsy ( TBLB)
mediastinoscopy, and video-assisted thoracoscopic
surgery (VATS) have been found to be useful in procuring
lung as well as intra-thoracic lymph node material3,4,10,50.
Presence of non-caseating epithelioid cell granulomas in
tissue biopsy specimens confirms the diagnosis of
sarcoidosis. Mere presence of non-caseating granulomas
must not be taken as proof of sarcoidosis. A complete and
thorough history of occupational and environmental
exposure, medication use, and medical history must be
obtained and other known causes of granulomatous
inflammation must be excluded before a patient is
labelled as having sarcoidosis. The difficulty in diagnosis
is further compounded by the fact that we have observed
necrosis in granulomatous lesions in some of the patients
with sarcoidosis at our centre4 and this renders
differentiation from tuberculosis very difficult.
Management
The algorithm for the practical management of patients
with sarcoidosis is depicted in Figure 1. Corticosteroids
have been the mainstay of therapy in patients with
sarcoidosis51. Though there are reports of short-term
improvement, especially in patients with deteriorating
lung function or serious extra-pulmonary disease167, well
controlled clinical trials showing definitive improvement
in the long-term outcome with the use of glucocorticoids
are lacking. Also, the appropriate dosage, value of daily as
opposed to alternate day therapy, and the optimum
duration of treatment, are also unclear52.
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Asymptomatic patients with pulmonary sarcoidosis
should not receive corticosteroids. Once treatment is
initiated with corticosteroids, and an adequate interval of
time has elapsed, the patient should be critically reviewed
to assess the need for further continuing the treatment. If
the response is considered appropriate, corticosteroids
should be gradually tapered while following the patients
clinically, radiologically, and physiologically. The patients
should be very carefully monitored for the rest of their
lifetime for any recurrences, as reactivation is not
uncommon even after prolonged periods of remission.
We have observed that prednisolone treatment resulted
in significant improvement in pulmonary functions, but
the values returned to the baseline once the corticosteroid
treatment was stopped3. Prednisolone treatment also
resulted in a significant reduction in peripheral blood and
BAL fluid complement and immunoglobulin levels. These
findings suggest peripheral blood lymphopenia and
lymphocytic alveolitis which improves with corticosteroid
treatment43-46.
Even steroid responsive sarcoidosis, particularly stage II
or stage III disease, has been reported to relapse in about
Fig. 1 : Algorithm for the evaluation and management of patients with sarcoidosis.
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25 per cent patients after stopping steroid treatment50.
Our experience with corticosteroid treatment has been
similar. Nineteen of the 21 patients (90.4%) who relapsed
in the series we reported3,4 had stage II or III disease. The
following correlated with the development of relapse:
history of malaise; presence of crepitations; wheezing;
peripheral blood eosinophilia; pre-treatment FEV
1
/FVC (%)
less than 65 per cent predicted. Muller53 observed that
eosinophilia was a favourable prognostic sign in patients
with tuberculosis. We observed the exact opposite in
patients with sarcoidosis3. To the best of our knowledge,
the observation that eosinophilia is a poor prognostic
marker in patients with sarcoidosis has never been
reported till date.
Several cytotoxic agents such as methotrexate,
azathioprine, and non-cytotoxic agents such as hydroxyl
chloroquine, thalidomide, ketoconazole among others,
have been explored to treat patients with sarcoidosis51.
These agents can cause severe adverse drug reactions
which may limit their use. Definitive benefits with these
agents is also not established. Further work is required to
clarify these issues. Till a consensus is evolved, these agents
should be used only by an experienced clinician.
Treatment should be tailored to the needs of the
individual case.
Learning points
 In India sarcoidosis is an under-diagnosed disease. All
ethnic groups in the Indian sub-continent are affected
by sarcoidosis.
 Most of the Indian patients with sarcoidosis are males;
the majority presenting late in the fourth or fifth
decade of their life.
 Constitutional symptoms such as fever, fatigue,
malaise, and weight loss have been observed to occur
more often in Indian patients.
  In Indian patients with sarcoidosis, it has been
observed that while the chest radiographs may look
startling, patients may manifest minimal symptoms
(clinico-radiographic dissociation).
 Depending on the organ systems involved, patients
with sarcoidosis present themselves to various
specialities; pulmonary involvement is by far the
commonest. Acute presentation in the form of
“Löfgren’s syndrome” and “Heerfordt’s syndrome” is
uncommon in Indian patients.
 Pulmonary function abnormalities were suggestive
of a mixed obstructive and restrictive ventilatory
defect; however, an obstructive defect was
predominantly observed.
 For asymptomatic patients with pulmonary
sarcoidosis, no therapy is required. In symptomatic
patients, or those with complications, corticosteroids
remain the mainstay of treatment. Corticosteroid
treatment usually results in significant symptom
resolution and improvement in pulmonary functions,
but the values return to the baseline once the
treatment is stopped. Occasionally, steroid-sparing
alternative treatments may be beneficial. Treatment
should be tailored to suit the needs of the individual
patient under close clinical monitoring.
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